Poster: MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study

Abdulraheem Yacoub,Uma Borate,Raajit Rampal,Haris Ali,Eunice Wang,Aaron Gerds,Gabriela Hobbs,Marina Kremyanskaya,Elliott Winton,Casey O'Connell,Swati Goel,Stephen Oh,Gary Schiller,Albert Assad,Sue Erickson-Viitanen,Feng Zhou,Naval Daver

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览8

暂无评分

摘要

Add-on parsaclisib showed promising efficacy and combination therapy was generally well-tolerated in myelofibrosis patients with low or higher baseline PC.

查看译文

关键词

MPN,myelofibrosis,platelet count,PI3K,ruxolitinib,Phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要